ArticleFrontiers in cardiovascular medicine2026
A case report: Transcatheter aortic valve replacement via femoral artery for aortic regurgitation post-CARVAR.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 26-year-old male patient experienced recurrent severe aortic regurgitation accompanied by left ventricular enlargement and a left ventricular ejection fraction of 17.7% 8 years after undergoing comprehensive aortic root and valve repair (CARVAR). Given the high risks associated with redo sternotomy and the patient's explicit refusal of both redo sternotomy and heart transplantation, a multidisciplinary consultation led to the decision to perform transcatheter aortic valve replacement (TAVR) as a transitional treatment. The transvalvular procedure was performed with snare-assisted valve delivery devices and ultra-high release technique. Postoperative echocardiography demonstrated normal valve function without perivalvular leakage, with significant improvement in cardiac function compared to baseline. This case illustrates that TAVR can serve as an effective transitional therapeutic strategy for high-risk patients with recurrent aortic regurgitation following CARVAR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.